Investment update - Paraytec Limited

Braveheart Investment Group plc
29 November 2023
 

29 November 2023

 

Braveheart Investment Group plc

("Braveheart" or the "Company")

 

Investment update - Paraytec Limited

 

Braveheart Investment Group (AIM: BRH), provides the following update on Paraytec Limited ("Paraytec"), a company within its investment portfolio. Paraytec develops high performance specialist detectors for the analytical and life sciences instrumentation markets.

 

Paraytec has informed Braveheart that it has secured its first commercial sales contract for the CX300 Optical Particle detector instrument (the "CX300 instrument"), to Nottingham Trent University ("NTU").  The instrument will be installed in the "EX-Cell group" at NTU, led by Prof Elisabetta Verderio Edwards, who's work focuses on the role of extracellular factors in cell survival in conditions of neurodegeneration and tissue repair. The CX300 instrument will be used to further their Alzheimer's, Dementia and Parkinson's research at NTU.

 

The Directors of Paraytec believe that this sale of the CX300 instrument could be the first of many to UK and European research laboratories.

 

Trevor Brown, CEO of Braveheart, commented:

"This sales contract with NTU is the first commercial sale of the CX300 instrument by Paraytec, justifying our investment in the company and its development in the CX300 instrument, as well as Paraytec's continuing commitment to innovation."

 

Braveheart holds a 100% equity interest in Paraytec. In addition, Braveheart has provided unsecured interest free loans to Paraytec totalling £1,155,200 as at 31 March 2023.

 

For further information:



Braveheart Investment Group plc

Tel: 01738 587555

Trevor Brown CEO

 




Allenby Capital Limited (Nominated Adviser and Joint Broker)

Tel: 020 3328 5656

James Reeve / George Payne

 




Peterhouse Capital Limited (Joint Broker)

Tel: 020 7469 0936

Duncan Vasey / Lucy Williams


 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings